Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A concise, practice-focused summary of the 2026 GINA Strategy Report, highlighting new recommendations on inhaled corticosteroid–formoterol (AIR) strategies, severe asthma biologic guidance, and acute care updates.
A large UK study reveals that over two-thirds of biologic-eligible severe asthma patients improve without biologic therapy, identifying distinct exacerbation trajectories linked to blood eosinophil levels and disease phenotype.
SHARP registry data reveal that biologic therapies improve clinical outcomes equally in severe asthma patients irrespective of smoking status, challenging prevailing prescribing hesitancy and advocating inclusive treatment approaches.
Earlier initiation of biologic therapies in severe asthma improves clinical remission rates, reduces exacerbations, preserves lung function, and decreases corticosteroid dependence, supporting a shift from reserving to preserving treatment
The PASSAGE phase 4 study reveals tezepelumab significantly reduces exacerbation rates and improves lung function and quality of life in a broad US severe asthma population, including underrepresented groups and varied phenotypes.
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t